Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

iQIYI

Nerdy

Penny stocks to buy according to analysts The post Penny Stocks To Buy Today? 3 To Watch With Price Targets Up To 1,152% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Today? 3 To Watch With Price Targets Up To 1,152%

NEW YORK , May 23, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced the appointment of Schond L. Greenway as Chief Financial Officer.

MindMed Appoints Schond L. Greenway as Chief Financial Officer

- Positive safety and tolerability results support the advancement of MM-110 and guide the Phase 2a dose design in individuals undergoing supervised opioid withdrawal - - Phase 2a trial remains on track to initiate in Q2 2022 - NEW YORK , May 19, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced topline results from the Phase 1 placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics and neurocognitive effects of MM-110 in 108 healthy volunteers. The results showed favorable safety and tolerability, support the advancement of MM-110, and have guided the Phase 2a dose, schedule, and design in individuals undergoing supervised opioid withdrawal.

MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal

Mind Medicine(NASDAQ:MNMD ) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Rob Barrow - CEO Dan Karlin - Chief Medical Officer Miri Halperin Wernli - Executive President Conference Call Participants Patrick Trucchio - H.C. Wainwright Michael Okunewitch - Maxim Elemer Piros - ROTH Capital Sepehr Manochehry - Eight Capital Tania Armstrong-Whitworth - Canaccord Genuity Operator Good morning and welcome to the Mind Medicine First Quarter 2022 Financial Results and Corporate Update Conference Call.

Mind Medicine(MNMD) CEO Rob Barrow on Q1 2022 Results - Earnings Call Transcript

- Advanced clinical programs for three lead drug candidates - - Strengthened leadership team with the appointment of Francois Lilienthal, MD as Chief Commercial Officer - - Cash runway through key clinical readouts in 2023 and into 2024 - - Company to host conference call today at 8:30 AM ET - NEW YORK , May 16, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended March 31, 2022. "The outset of 2022 was marked by significant progress across all aspects of the company that propelled our business forward, as we continued to advance and de-risk our three lead product candidates: MM-120 for the treatment of generalized anxiety disorder, MM-402 for the treatment of core symptoms of autism spectrum disorder, and MM-110 for the management of opioid use disorder," said Robert Barrow, Chief Executive Officer and Director of MindMed.

MindMed Reports First Quarter 2022 Financial Results and Business Highlights

Mind Medicine (MNMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Mind Medicine (MNMD)

- Results from the placebo-controlled investigator-initiated trial, conducted at the University Hospital Basel (UHB), demonstrate the significant, long-lasting beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression - - Data further validates MindMed's therapeutic approach and supports the clinical development of MM-120 for the treatment of Generalized Anxiety Disorder - - Data was featured in an oral presentation on May 11, 2022 at 5:05am EDT / 10:05am BST - NEW YORK , May 11, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Prof. Matthias Liechti and Dr. Friederike Holze, MindMed collaborators at University Hospital Basel (UHB), have released positive topline data from a Phase 2 placebo-controlled investigator-initiated clinical trial evaluating LSD in the treatment of anxiety disorders.

MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders

NEW YORK , May 9, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Monday, May 16, 2022, at 8:30 a.m. EDT to discuss its financial results for the quarter ended March 31, 2022 and provide a business update.

MindMed to Host Earnings Call to Discuss First Quarter 2022 Financial Results and Provide Business Update

Mountain Crest Acquisition Corp II

Sunworks

Alaunos Therapeutics

Penny stocks with huge potential according to analysts in 2022. The post Penny Stocks With Huge Potential According To 4 Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks With Huge Potential According To 4 Wall Street Analysts

Adobe

Atai Life Sciences BV

COMPASS Pathways

Cybin

Delta Air Lines

GW Pharmaceuticals

Home Depot

Johnson & Johnson

JPMorgan Chase & Co

Lowe's

Netflix

PayPal

Twitter

Wells Fargo

Walmart

Interested in Investing in Psychedelics? Check Out This Podcast.

- "LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy" will present the most recent and robust data on LSD in patients with anxiety - - This study builds on decades of research on the effects of LSD in humans - NEW YORK , April 14, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Dr. Frederike Holze and Prof. Dr. Matthias Liechti, MindMed collaborators at University Hospital Basel (UHB), will present results from the LSD-Assist Study, a Phase 2 investigator-initiated clinical trial of LSD in the treatment of anxiety disorders, at London's PSYCH Symposium on May 11, 2022.

MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety Disorders at PSYCH Symposium

- Dr. Lilienthal brings over 20 years of global biopharmaceutical experience, leading the development and commercialization of innovative medicines across multiple therapeutic areas including psychiatry and neurology - NEW YORK , April 5, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Francois Lilienthal, MD as Chief Commercial Officer. With more than two decades of global biopharmaceutical experience and after serving as a consultant for MindMed over the past six months, Dr. Lilienthal will step into this role to support the advancement of the Company's clinical development programs.

MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

Field Trip Health Ltd

Psychedelic medical treatments and therapies are gaining in popularity, and these psychedelic stocks could benefit as the market emerges. The post 3 Psychedelic Stocks to Buy for Oregon's Magic Mushroom Bill appeared first on InvestorPlace.

3 Psychedelic Stocks to Buy for Oregon's Magic Mushroom Bill

Mind Medicine (MindMed) Inc. (MNMD) CEO Rob Barrow on Q4 2021 Results - Earnings Call Transcript

- FDA cleared MindMed's Investigational New Drug (IND) application for Phase 2b dose optimization trial of MM-120 - - Progressed development programs for all three lead product candidates - - Cash balance of $133.5 million at year end 2021 - - Company to host earnings conference call today at 8:30 AM EDT - NEW YORK , March 28, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the full-year ended December 31, 2021. "2021 was a year of major advancements across all aspects of MindMed, with significant growth in our organization, development programs and research collaborations.

MindMed Reports Full Year 2021 Financial Results and Business Highlights

NEW YORK , March 25, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that its Chief Financial Officer, David Guebert, will be retiring from his position on March 31, 2022. "On behalf of the Board of Directors and Executive team, I would like to thank Dave, who was essential to the founding and early growth of our organization," said Robert Barrow, Chief Executive Officer and Director of MindMed.

MindMed Announces Transition of CFO

Bitfarms Ltd

XPeng

Science Applications International

After markets closed Wednesday afternoon, Fortuna Silver reported a quarterly revenue beat and an earnings miss.

Earnings Previews: Bitfarms, Mind Medicine, SAIC, Xpeng

NEW YORK , March 21, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Monday, March 28, 2022, at 8:30 a.m. EDT to discuss its financial results for the full year ended December 31, 2021 and provide a business update.

MindMed to Host Earnings Call to Discuss Full-Year 2021 Financial Results and Provide Business Update

NEW YORK, March 2, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, today announced the peer-reviewed publication of a study directly comparing the acute effects of Lysergic Acid Diethylamide (LSD) and psilocybin in healthy subjects. The data, published in Neuropsychopharmacology and titled, " Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects ", demonstrates that the key differences between LSD and psilocybin are dose-dependent rather than substance-dependent.

MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects

- Automatic conversion to be effective March 14, 2022 - NEW YORK, Feb. 23, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today  that all the Company's issued and outstanding multiple voting shares (the "Multiple Voting Shares") will undergo a mandatory conversion into subordinate voting shares (the "Subordinate Voting Shares") (the "Conversion"), in accordance with the Company's Articles. The Conversion will be effective March 14, 2022 (the "Effective Date").

MindMed Converts Multiple Voting Shares to Subordinate Voting Shares

(Kitco News) - America faces a serious mental health crisis, this is how MindMed aims to fix this

America faces a serious mental health crisis, this is how MindMed aims to fix this

Media company Global Trac Solutions, Inc. (OTCP:PSYC) and authorities behind psychedelic news and information platform Psychedelic Spotlight, announced that Psychedelic Spotlight will host its first “CEO Roundtable” on Feb. 15. The event is scheduled to be streamed live on YouTube via The Psychedelic Investor channel, and will be moderated by James Hallifax, journalist and content director for Psychedelic Spotlight.

Cybin, MindMed, and Field Trip Health Headline PSYC's First CEO Round Table Event.

The clinical-stage biopharmaceutical company benefited from an increased interest in companies working on psychedelic therapies.

Why Shares of Mind Medicine Jumped 13.4% on Wednesday

Few catalysts can move healthcare stocks like a regulatory clearance can - and MNMD stock could be 2022's top psychedelics-sector investment. The post FDA Greenlight Sets the Stage for Upside With Mind Medicine appeared first on InvestorPlace.

FDA Greenlight Sets the Stage for Upside With Mind Medicine

Biofrontera

Bit Digital, Inc

Hive Blockchain Technologies Ltd

Indonesia Energy Corp Ltd

Reddit penny stocks to watch in February. The post 5 Penny Stocks To Buy Right Now According To Reddit Social Sentiment appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Mind Medicine MindMed Stock (MNMD)